Navigation Links
Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
Date:10/15/2007

Accellerase(TM) 1000 is launched at the Cellulosic Ethanol Summit in

Washington, DC

ROCHESTER, N.Y., Oct. 15 /PRNewswire/ -- Genencor, a division of Danisco A/S, today announced a new product, Accellerase(TM) 1000, the first ever commercially available biomass enzyme developed specifically for second generation biorefineries. Accellerase(TM) 1000 contains a potent complex of enzymes that reduces complex lignocellulosic biomass into fermentable sugars -- an indispensable step for the production of cellulosic ethanol.

Genencor has been developing its biomass enzymes for well over 10 years. The effort was partially supported by contracts with the US Department of Energy's (DOE) National Renewable Energy Laboratory (NREL). Commercial interest in second generation biorefineries, driven in part by government policies to reduce the emission of greenhouse gases and increase energy independence, has accelerated over the past two years in the USA and around the world. Accellerase(TM) 1000 will fill a large unmet need for reliable biomass enzyme supply to pilot and demonstration plant developers who are actively working on process development, scale up and integration. Accellerase(TM) 1000 is the first in what the company expects to be a family of products tailored to different biomass feedstocks and system conditions. The key features that are expected to be important at commercial scale are already built into this first product.

"The biofuels industry is at an inflection point with the development of cellulosic ethanol plants at the pilot and demonstration scale," said Jack Huttner, vice president of biorefinery business development. "Every biorefinery developer needs to know how enzymes will work in their system. This product aims to address that need and to start a dialogue with potential partners about customized solutions and supply at the industrial scale."

"Enzymes, such as those developed by Genencor, will serve as catalysts to the commercial-scale viability of cellulosic ethanol, a clean source of energy to help meet President Bush's goal of reducing our reliance on oil," DOE Assistant Secretary Andy Karsner said. "Ethanol from new feed stocks will not only give America more efficient fuel options to help transform our transportation sector, but increasing its use will help reduce greenhouse gas emissions."

Product information and technical applications information is available on the website http://www.genencor.com/cellulosicethanol. Accellerase(TM) 1000 will be available for sample and sale immediately. Call the customer relations numbers below or email customer_relations@genencor.com to place your order.

Europe/Africa /Middle East: +31 71 5686 168

United States and Canada: +1 800 847 5311

Asia/Pacific: +1 65 6511 5600

Latin America: +54 11 5199 9550

HIGHLIGHTS OF ACCELLERASE BENEFITS

-- Enhanced saccharification performance on a variety of feedstocks.

-- Ability to operate in simultaneous saccharification and fermentation

(SSF) processes, two step sequential hydrolysis and fermentation (SHF)

processes or hybrids of the two.

-- High beta-glucosidase activity to minimize residual cellobiose, which

may lead to a higher saccharification and ultimately to a faster

ethanol fermentation. Yields may also be improved.

-- Unclarified product. The remaining nutrients from enzyme production

are available to the yeast in addition to the fermentable sugars

produced by saccharification.

-- Minimal formulation to ensure that enzyme formulation chemicals do not

interfere with saccharification carbohydrate profile analysis or

subsequent yeast fermentation.

About Genencor

Genencor, a division of Danisco A/S, is a leader in the industrial biotechnology sector. In more than 40 countries, Genencor's 1,500 employees develop and market innovative enzymes and biobased solutions to improve the performance and reduce the environmental impact of a wide variety of industries, from laundry detergents to transportation fuels. Genencor also develops and produces enzymes for the food, beverage and animal nutrition industries, which are sold under the Danisco brand. In partnership with our customers, technology leaders and other stakeholders, Genencor's cutting-edge biotech platform provides competitive and sustainable solutions to the world, positioning Genencor as one of the leaders in the emerging biobased economy.


'/>"/>
SOURCE Genencor
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):